<div class="xtend">
         <div class="xtend_ce"><a id="pl.1.1"></a><var>1.1</var>A bill for an act<br />
            		
         </div><a id="pl.1.2"></a><var>1.2</var>relating to public safety; granting the Board of Pharmacy cease and desist <br />
         		<a id="pl.1.3"></a><var>1.3</var>authority to prevent the sale of synthetic drugs; modifying laws governing <br />
         		<a id="pl.1.4"></a><var>1.4</var>misbranding drugs, adulterated drugs; expanding the definition of drug; repealing <br />
         		<a id="pl.1.5"></a><var>1.5</var>the sunset and legislative reporting requirement for the Board of Pharmacy's <br />
         		<a id="pl.1.6"></a><var>1.6</var>emergency drug scheduling authority; providing for mandatory restitution when <br />
         		<a id="pl.1.7"></a><var>1.7</var>a person is convicted for selling controlled substance under false pretense of <br />
         		<a id="pl.1.8"></a><var>1.8</var>being legal; establishing a public education plan; appropriating money;amending <br />
         		<a id="pl.1.9"></a><var>1.9</var>Minnesota Statutes 2012, sections 151.01, subdivision 5; 151.06, subdivision <br />
         		<a id="pl.1.10"></a><var>1.10</var>1a, by adding a subdivision; 151.26, subdivision 1; 151.34; 151.35; 151.36; <br />
         		<a id="pl.1.11"></a><var>1.11</var>152.02, subdivision 8b.<br />
         		<a id="pl.1.12"></a><var>1.12</var>BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:<br />
         		<br />
         		<a id="bill.0.1.0"></a><a id="pl.1.13"></a><var>1.13</var>&nbsp;&nbsp;&nbsp;&nbsp;Section 1. Minnesota Statutes 2012, section 151.01, subdivision 5, is amended to read:<br />
         		<a id="pl.1.14"></a><var>1.14</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 5. <b>Drug.</b> The term "drug" means all medicinal substances and preparations <br />
         		<a id="pl.1.15"></a><var>1.15</var>recognized by the United States Pharmacopoeia and National Formulary, or any revision <br />
         		<a id="pl.1.16"></a><var>1.16</var>thereof, and all substances and preparations intended for external and internal use in the <br />
         		<a id="pl.1.17"></a><var>1.17</var>diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals, <br />
         		<a id="pl.1.18"></a><var>1.18</var>and all substances and preparations, other than food, intended to affect the structure or <br />
         		<a id="pl.1.19"></a><var>1.19</var>any function of the bodies of humans or other animals. The term drug shall also mean <br />
         		<a id="pl.1.20"></a><var>1.20</var>any compound, substance, or derivative that is not approved for human consumption by <br />
         		<a id="pl.1.21"></a><var>1.21</var>the United States Food and Drug Administration or specifically permitted for human <br />
         		<a id="pl.1.22"></a><var>1.22</var>consumption under Minnesota law, and when introduced into the body induces an effect <br />
         		<a id="pl.1.23"></a><var>1.23</var>similar to that of a Schedule I or Schedule II controlled substance listed in section 152.02, <br />
         		<a id="pl.1.24"></a><var>1.24</var>subdivisions 2 and 3, or Minnesota Rules, parts 6800.4210 and 6800.4220, regardless of <br />
         		<a id="pl.1.25"></a><var>1.25</var>whether the substance is marketed for the purpose of human consumption.<br />
         		<a id="pl.1.26"></a><var>1.26</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2014.<br />
         		<br />
         		<a id="bill.0.2.0"></a><a id="pl.2.1"></a><var>2.1</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 2. Minnesota Statutes 2012, section 151.06, subdivision 1a, is amended to read:<br />
         		<a id="pl.2.2"></a><var>2.2</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 1a. <b>Disciplinary action</b><b> Cease and desist orders</b><b>.</b> It shall be grounds for <br />
         		<a id="pl.2.3"></a><var>2.3</var>disciplinary action by the Board of Pharmacy against the registration of the pharmacy if <br />
         		<a id="pl.2.4"></a><var>2.4</var>the Board of Pharmacy determines that any person with supervisory responsibilities at the <br />
         		<a id="pl.2.5"></a><var>2.5</var>pharmacy sets policies that prevent a licensed pharmacist from providing drug utilization <br />
         		<a id="pl.2.6"></a><var>2.6</var>review and patient counseling as required by rules adopted under subdivision 1. The <br />
         		<a id="pl.2.7"></a><var>2.7</var>Board of Pharmacy shall follow the requirements of chapter 14 in any disciplinary actions <br />
         		<a id="pl.2.8"></a><var>2.8</var>taken under this section. (a) Whenever it appears to the board that a person has engaged in <br />
         		<a id="pl.2.9"></a><var>2.9</var>an act or practice constituting a violation of a law, rule, or other order related to the duties <br />
         		<a id="pl.2.10"></a><var>2.10</var>and responsibilities entrusted to the board, the board may issue and cause to be served <br />
         		<a id="pl.2.11"></a><var>2.11</var>upon the person an order requiring the person to cease and desist from violations.<br />
         		<a id="pl.2.12"></a><var>2.12</var>(b) The cease and desist order must state the reasons for the issuance of the order <br />
         		<a id="pl.2.13"></a><var>2.13</var>and must give reasonable notice of the rights of the person to request a hearing before <br />
         		<a id="pl.2.14"></a><var>2.14</var>an administrative law judge. A hearing must be held not later than ten days after the <br />
         		<a id="pl.2.15"></a><var>2.15</var>request for the hearing is received by the board. After the completion of the hearing, <br />
         		<a id="pl.2.16"></a><var>2.16</var>the administrative law judge shall issue a report within ten days. Within 15 days after <br />
         		<a id="pl.2.17"></a><var>2.17</var>receiving the report of the administrative law judge, the board shall issue a further order <br />
         		<a id="pl.2.18"></a><var>2.18</var>vacating or making permanent the cease and desist order. The time periods provided in <br />
         		<a id="pl.2.19"></a><var>2.19</var>this provision may be waived by agreement of the executive director of the board and the <br />
         		<a id="pl.2.20"></a><var>2.20</var>person against whom the cease and desist order was issued. If the person to whom a cease <br />
         		<a id="pl.2.21"></a><var>2.21</var>and desist order is issued fails to appear at the hearing after being duly notified, the person <br />
         		<a id="pl.2.22"></a><var>2.22</var>is in default, and the proceeding may be determined against that person upon consideration <br />
         		<a id="pl.2.23"></a><var>2.23</var>of the cease and desist order, the allegations of which may be considered to be true. Unless <br />
         		<a id="pl.2.24"></a><var>2.24</var>otherwise provided, all hearings must be conducted according to chapter 14. The board <br />
         		<a id="pl.2.25"></a><var>2.25</var>may adopt rules of procedure concerning all proceedings conducted under this subdivision.<br />
         		<a id="pl.2.26"></a><var>2.26</var>(c) If no hearing is requested within 30 days of service of the order, the cease and <br />
         		<a id="pl.2.27"></a><var>2.27</var>desist order will become permanent.<br />
         		<a id="pl.2.28"></a><var>2.28</var>(d) A cease and desist order issued under this subdivision remains in effect until <br />
         		<a id="pl.2.29"></a><var>2.29</var>it is modified or vacated by the board. The administrative proceeding provided by this <br />
         		<a id="pl.2.30"></a><var>2.30</var>subdivision, and subsequent appellate judicial review of that administrative proceeding, <br />
         		<a id="pl.2.31"></a><var>2.31</var>constitutes the exclusive remedy for determining whether the board properly issued the <br />
         		<a id="pl.2.32"></a><var>2.32</var>cease and desist order and whether the cease and desist order should be vacated or made <br />
         		<a id="pl.2.33"></a><var>2.33</var>permanent.<br />
         		<a id="pl.2.34"></a><var>2.34</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2014, and applies to <br />
         		<a id="pl.2.35"></a><var>2.35</var>violations occurring on or after that date.<br />
         		<br />
         		<a id="bill.0.3.0"></a><a id="pl.3.1"></a><var>3.1</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 3. Minnesota Statutes 2012, section 151.06, is amended by adding a subdivision <br />
         		<a id="pl.3.2"></a><var>3.2</var>to read:<br />
         		<a id="pl.3.3"></a><var>3.3</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 1b. <b>Enforcement of violations of cease and desist orders.</b> (a) Whenever <br />
         		<a id="pl.3.4"></a><var>3.4</var>the board under subdivision 1a seeks to enforce compliance with a cease and desist <br />
         		<a id="pl.3.5"></a><var>3.5</var>order that has been made permanent, the allegations of the cease and desist order are <br />
         		<a id="pl.3.6"></a><var>3.6</var>considered conclusively established for purposes of proceeding under subdivision 1a for <br />
         		<a id="pl.3.7"></a><var>3.7</var>permanent or temporary relief to enforce the cease and desist order. Whenever the board <br />
         		<a id="pl.3.8"></a><var>3.8</var>under subdivision 1a seeks to enforce compliance with a cease and desist order when a <br />
         		<a id="pl.3.9"></a><var>3.9</var>hearing or hearing request on the cease and desist order is pending, or the time has not <br />
         		<a id="pl.3.10"></a><var>3.10</var>yet expired to request a hearing on whether a cease and desist order should be vacated or <br />
         		<a id="pl.3.11"></a><var>3.11</var>made permanent, the allegations in the cease and desist order are considered conclusively <br />
         		<a id="pl.3.12"></a><var>3.12</var>established for the purposes of proceeding under subdivision 1a for temporary relief to <br />
         		<a id="pl.3.13"></a><var>3.13</var>enforce the cease and desist order.<br />
         		<a id="pl.3.14"></a><var>3.14</var>(b) Notwithstanding this subdivision or subdivision 1a, the person against whom <br />
         		<a id="pl.3.15"></a><var>3.15</var>the cease and desist order is issued and who has requested a hearing under subdivision 1a <br />
         		<a id="pl.3.16"></a><var>3.16</var>may, within 15 days after service of the cease and desist order, bring an action in Ramsey <br />
         		<a id="pl.3.17"></a><var>3.17</var>County District Court for issuance of an injunction to suspend enforcement of the cease <br />
         		<a id="pl.3.18"></a><var>3.18</var>and desist order pending a final decision of the board under subdivision 1a to vacate or <br />
         		<a id="pl.3.19"></a><var>3.19</var>make permanent the cease and desist order. The court shall determine whether to issue <br />
         		<a id="pl.3.20"></a><var>3.20</var>such an injunction based on traditional principles of temporary relief.<br />
         		<a id="pl.3.21"></a><var>3.21</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2014, and applies to <br />
         		<a id="pl.3.22"></a><var>3.22</var>violations occurring on or after that date.<br />
         		<br />
         		<a id="bill.0.4.0"></a><a id="pl.3.23"></a><var>3.23</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 4. Minnesota Statutes 2012, section 151.26, subdivision 1, is amended to read:<br />
         		<a id="pl.3.24"></a><var>3.24</var>&nbsp;&nbsp;&nbsp;&nbsp;Subdivision 1. <b>Generally.</b> Nothing in this chapter shall subject a person duly <br />
         		<a id="pl.3.25"></a><var>3.25</var>licensed in this state to practice medicine, dentistry, or veterinary medicine, to inspection <br />
         		<a id="pl.3.26"></a><var>3.26</var>by the State Board of Pharmacy, nor prevent the person from administering drugs, <br />
         		<a id="pl.3.27"></a><var>3.27</var>medicines, chemicals, or poisons in the person's practice, nor prevent a duly licensed <br />
         		<a id="pl.3.28"></a><var>3.28</var>practitioner from furnishing to a patient properly packaged and labeled drugs, medicines, <br />
         		<a id="pl.3.29"></a><var>3.29</var>chemicals, or poisons as may be considered appropriate in the treatment of such patient; <br />
         		<a id="pl.3.30"></a><var>3.30</var>unless the person is engaged in the dispensing, sale, or distribution of drugs and the board <br />
         		<a id="pl.3.31"></a><var>3.31</var>provides reasonable notice of an inspection.<br />
         		<a id="pl.3.32"></a><var>3.32</var>Except for the provisions of section 
         <statute_ref>151.37</statute_ref>, nothing in this chapter applies to or <br />
         		<a id="pl.3.33"></a><var>3.33</var>interferes with the dispensing, in its original package and at no charge to the patient, of a <br />
         		<a id="pl.3.34"></a><var>3.34</var>legend drug, other than a controlled substance, that was packaged by a manufacturer and <br />
         		<a id="pl.3.35"></a><var>3.35</var>provided to the dispenser for distribution as a professional sample.<br />
         		<a id="pl.4.1"></a><var>4.1</var>Nothing in this chapter shall prevent the sale of drugs, medicines, chemicals, or <br />
         		<a id="pl.4.2"></a><var>4.2</var>poisons at wholesale to licensed physicians, dentists and veterinarians for use in their <br />
         		<a id="pl.4.3"></a><var>4.3</var>practice, nor to hospitals for use therein.<br />
         		<a id="pl.4.4"></a><var>4.4</var>Nothing in this chapter shall prevent the sale of drugs, chemicals, or poisons either <br />
         		<a id="pl.4.5"></a><var>4.5</var>at wholesale or retail for use for commercial purposes, or in the arts, nor interfere with the <br />
         		<a id="pl.4.6"></a><var>4.6</var>sale of insecticides, as defined in Minnesota Statutes 1974, section 
         <statute_ref>24.069</statute_ref>, and nothing in <br />
         		<a id="pl.4.7"></a><var>4.7</var>this chapter shall prevent the sale of common household preparations and other drugs, <br />
         		<a id="pl.4.8"></a><var>4.8</var>chemicals, and poisons sold exclusively for use for nonmedicinal purposes; provided that <br />
         		<a id="pl.4.9"></a><var>4.9</var>this exception does not apply to any compound, substance, or derivative that is not approved <br />
         		<a id="pl.4.10"></a><var>4.10</var>for human consumption by the United States Food and Drug Administration or specifically <br />
         		<a id="pl.4.11"></a><var>4.11</var>permitted for human consumption under Minnesota law, and when introduced into the body <br />
         		<a id="pl.4.12"></a><var>4.12</var>induces an effect similar to that of a Schedule I or Schedule II controlled substance listed in <br />
         		<a id="pl.4.13"></a><var>4.13</var>section 152.02, subdivisions 2 and 3, or Minnesota Rules, parts 6800.4210 and 6800.4220, <br />
         		<a id="pl.4.14"></a><var>4.14</var>regardless of whether the substance is marketed for the purpose of human consumption.<br />
         		<a id="pl.4.15"></a><var>4.15</var>Nothing in this chapter shall apply to or interfere with the vending or retailing <br />
         		<a id="pl.4.16"></a><var>4.16</var>of any nonprescription medicine or drug not otherwise prohibited by statute which is <br />
         		<a id="pl.4.17"></a><var>4.17</var>prepackaged, fully prepared by the manufacturer or producer for use by the consumer, and <br />
         		<a id="pl.4.18"></a><var>4.18</var>labeled in accordance with the requirements of the state or federal Food and Drug Act; nor <br />
         		<a id="pl.4.19"></a><var>4.19</var>to the manufacture, wholesaling, vending, or retailing of flavoring extracts, toilet articles, <br />
         		<a id="pl.4.20"></a><var>4.20</var>cosmetics, perfumes, spices, and other commonly used household articles of a chemical <br />
         		<a id="pl.4.21"></a><var>4.21</var>nature, for use for nonmedicinal purposes; provided that this exception does not apply <br />
         		<a id="pl.4.22"></a><var>4.22</var>to any compound, substance, or derivative that is not approved for human consumption <br />
         		<a id="pl.4.23"></a><var>4.23</var>by the United States Food and Drug Administration or specifically permitted for human <br />
         		<a id="pl.4.24"></a><var>4.24</var>consumption under Minnesota law, and when introduced into the body induces an effect <br />
         		<a id="pl.4.25"></a><var>4.25</var>similar to that of a Schedule I or Schedule II controlled substance listed in section 152.02, <br />
         		<a id="pl.4.26"></a><var>4.26</var>subdivisions 2 and 3, or Minnesota Rules, parts 6800.4210 and 6800.4220, regardless of <br />
         		<a id="pl.4.27"></a><var>4.27</var>whether the substance is marketed for the purpose of human consumption. Nothing in <br />
         		<a id="pl.4.28"></a><var>4.28</var>this chapter shall prevent the sale of drugs or medicines by licensed pharmacists at a <br />
         		<a id="pl.4.29"></a><var>4.29</var>discount to persons over 65 years of age.<br />
         		<a id="pl.4.30"></a><var>4.30</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2014.<br />
         		<br />
         		<a id="bill.0.5.0"></a><a id="pl.4.31"></a><var>4.31</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 5. Minnesota Statutes 2012, section 151.34, is amended to read:<br />
         		<a id="pl.4.32"></a><var>4.32</var><b>151.34 PROHIBITED ACTS.</b><br />
         		<a id="pl.4.33"></a><var>4.33</var>It shall be unlawful to:<br />
         		<a id="pl.5.1"></a><var>5.1</var>(1) manufacture, sell or deliver, hold or offer for sale any drug that is adulterated <br />
         		<a id="pl.5.2"></a><var>5.2</var>or misbranded;<br />
         		<a id="pl.5.3"></a><var>5.3</var>(2) adulterate or misbrand any drug;<br />
         		<a id="pl.5.4"></a><var>5.4</var>(3) receive in commerce any drug that is adulterated or misbranded, and to deliver or <br />
         		<a id="pl.5.5"></a><var>5.5</var>proffer delivery thereof for pay or otherwise;<br />
         		<a id="pl.5.6"></a><var>5.6</var>(4) refuse to permit entry or inspection, or to permit the taking of a sample, or to <br />
         		<a id="pl.5.7"></a><var>5.7</var>permit access to or copying of any record as authorized by this chapter;<br />
         		<a id="pl.5.8"></a><var>5.8</var>(5) remove or dispose of a detained or embargoed article in violation of this chapter;<br />
         		<a id="pl.5.9"></a><var>5.9</var>(6) alter, mutilate, destroy, obliterate, or remove the whole or any part of the labeling <br />
         		<a id="pl.5.10"></a><var>5.10</var>of, or to do any other act with respect to a drug, if such act is done while such drug is held <br />
         		<a id="pl.5.11"></a><var>5.11</var>for sale and results in such drug being adulterated or misbranded;<br />
         		<a id="pl.5.12"></a><var>5.12</var>(7) use for a person's own advantage or to reveal other than to the board or its <br />
         		<a id="pl.5.13"></a><var>5.13</var>authorized representative or to the courts when required in any judicial proceeding under <br />
         		<a id="pl.5.14"></a><var>5.14</var>this chapter any information acquired under authority of this chapter concerning any <br />
         		<a id="pl.5.15"></a><var>5.15</var>method or process which that is a trade secret and entitled to protection;<br />
         		<a id="pl.5.16"></a><var>5.16</var>(8) use on the labeling of any drug any representation or suggestion that an <br />
         		<a id="pl.5.17"></a><var>5.17</var>application with respect to such drug is effective under the federal act or that such drug <br />
         		<a id="pl.5.18"></a><var>5.18</var>complies with such provisions;<br />
         		<a id="pl.5.19"></a><var>5.19</var>(9) in the case of a manufacturer, packer, or distributor offering legend drugs for sale <br />
         		<a id="pl.5.20"></a><var>5.20</var>within this state, fail to maintain for transmittal or to transmit, to any practitioner licensed <br />
         		<a id="pl.5.21"></a><var>5.21</var>by applicable law to administer such drug who makes written request for information as to <br />
         		<a id="pl.5.22"></a><var>5.22</var>such drug, true and correct copies of all printed matter which that is required to be included <br />
         		<a id="pl.5.23"></a><var>5.23</var>in any package in which that drug is distributed or sold, or such other printed matter as is <br />
         		<a id="pl.5.24"></a><var>5.24</var>approved under the federal act. Nothing in this paragraph shall be construed to exempt <br />
         		<a id="pl.5.25"></a><var>5.25</var>any person from any labeling requirement imposed by or under provisions of this chapter;<br />
         		<a id="pl.5.26"></a><var>5.26</var>(10) conduct a pharmacy without a pharmacist in charge;<br />
         		<a id="pl.5.27"></a><var>5.27</var>(11) dispense a legend drug without first obtaining a valid prescription for that drug;<br />
         		<a id="pl.5.28"></a><var>5.28</var>(12) conduct a pharmacy without proper registration with the board;<br />
         		<a id="pl.5.29"></a><var>5.29</var>(13) practice pharmacy without being licensed to do so by the board; or<br />
         		<a id="pl.5.30"></a><var>5.30</var>(14) sell at retail federally restricted medical gases without proper registration with <br />
         		<a id="pl.5.31"></a><var>5.31</var>the board except as provided in this chapter.; or<br />
         		<a id="pl.5.32"></a><var>5.32</var>(15) sell any compound, substance, or derivative that is not approved for human <br />
         		<a id="pl.5.33"></a><var>5.33</var>consumption by the United States Food and Drug Administration or specifically permitted <br />
         		<a id="pl.5.34"></a><var>5.34</var>for human consumption under Minnesota law, and when introduced into the body induces <br />
         		<a id="pl.5.35"></a><var>5.35</var>an effect similar to that of a Schedule I or Schedule II controlled substance listed in <br />
         		<a id="pl.6.1"></a><var>6.1</var>section 152.02, subdivisions 2 and 3, or Minnesota Rules, parts 6800.4210 and 6800.4220, <br />
         		<a id="pl.6.2"></a><var>6.2</var>regardless of whether the substance is marketed for the purpose of human consumption.<br />
         		<a id="pl.6.3"></a><var>6.3</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2014, and applies to sales <br />
         		<a id="pl.6.4"></a><var>6.4</var>on or after that date.<br />
         		<br />
         		<a id="bill.0.6.0"></a><a id="pl.6.5"></a><var>6.5</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 6. Minnesota Statutes 2012, section 151.35, is amended to read:<br />
         		<a id="pl.6.6"></a><var>6.6</var><b>151.35 DRUGS, ADULTERATION.</b><br />
         		<a id="pl.6.7"></a><var>6.7</var>A drug shall be deemed to be adulterated:<br />
         		<a id="pl.6.8"></a><var>6.8</var>(1) if it consists in whole or in part of any filthy, putrid or decomposed substance; or <br />
         		<a id="pl.6.9"></a><var>6.9</var>if it has been produced, prepared, packed, or held under unsanitary conditions whereby it <br />
         		<a id="pl.6.10"></a><var>6.10</var>may have been rendered injurious to health, or whereby it may have been contaminated <br />
         		<a id="pl.6.11"></a><var>6.11</var>with filth; or if the methods used in, or the facilities or controls used for, its manufacture, <br />
         		<a id="pl.6.12"></a><var>6.12</var>processing, packing, or holding do not conform to or are not operated or administered <br />
         		<a id="pl.6.13"></a><var>6.13</var>in conformity with current good manufacturing practice as required under the federal <br />
         		<a id="pl.6.14"></a><var>6.14</var>act to assure that such drug is safe and has the identity, strength, quality, and purity <br />
         		<a id="pl.6.15"></a><var>6.15</var>characteristics, which it purports or is represented to possess; or the facility in which it <br />
         		<a id="pl.6.16"></a><var>6.16</var>was produced was not registered by the United States Food and Drug Administration or <br />
         		<a id="pl.6.17"></a><var>6.17</var>licensed by the board; or, its container is composed, in whole or in part, of any poisonous <br />
         		<a id="pl.6.18"></a><var>6.18</var>or deleterious substance which may render the contents injurious to health; or it bears <br />
         		<a id="pl.6.19"></a><var>6.19</var>or contains, for purposes of coloring only, a color additive which is unsafe within the <br />
         		<a id="pl.6.20"></a><var>6.20</var>meaning of the federal act, or it is a color additive, the intended use of which in or on drugs <br />
         		<a id="pl.6.21"></a><var>6.21</var>is for the purposes of coloring only, and is unsafe within the meaning of the federal act;<br />
         		<a id="pl.6.22"></a><var>6.22</var>(2) if it purports to be or is represented as a drug the name of which is recognized in <br />
         		<a id="pl.6.23"></a><var>6.23</var>the United States Pharmacopoeia or the National Formulary, and its strength differs from, <br />
         		<a id="pl.6.24"></a><var>6.24</var>or its quality or purity falls below, the standard set forth therein. Such determination as <br />
         		<a id="pl.6.25"></a><var>6.25</var>to strength, quality, or purity shall be made in accordance with the tests or methods of <br />
         		<a id="pl.6.26"></a><var>6.26</var>assay set forth in such compendium, or in the absence of or inadequacy of such tests or <br />
         		<a id="pl.6.27"></a><var>6.27</var>methods of assay, those prescribed under authority of the federal act. No drug defined <br />
         		<a id="pl.6.28"></a><var>6.28</var>in the United States Pharmacopoeia or the National Formulary shall be deemed to be <br />
         		<a id="pl.6.29"></a><var>6.29</var>adulterated under this paragraph because it differs from the standard of strength, quality, <br />
         		<a id="pl.6.30"></a><var>6.30</var>or purity therefor set forth in such compendium, if its difference in strength, quality, or <br />
         		<a id="pl.6.31"></a><var>6.31</var>purity from such standard is plainly stated on its label;<br />
         		<a id="pl.6.32"></a><var>6.32</var>(3) if it is not subject to the provisions of paragraph (2) of this section and its <br />
         		<a id="pl.6.33"></a><var>6.33</var>strength differs from, or its purity or quality differs from that which it purports or is <br />
         		<a id="pl.6.34"></a><var>6.34</var>represented to possess;<br />
         		<a id="pl.7.1"></a><var>7.1</var>(4) if any substance has been mixed or packed therewith so as to reduce its quality or <br />
         		<a id="pl.7.2"></a><var>7.2</var>strength, or substituted wholly or in part therefor.<br />
         		<a id="pl.7.3"></a><var>7.3</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2014.<br />
         		<br />
         		<a id="bill.0.7.0"></a><a id="pl.7.4"></a><var>7.4</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 7. Minnesota Statutes 2012, section 151.36, is amended to read:<br />
         		<a id="pl.7.5"></a><var>7.5</var><b>151.36 DRUGS, MISBRANDING.</b><br />
         		<a id="pl.7.6"></a><var>7.6</var>A drug shall be deemed to be misbranded:<br />
         		<a id="pl.7.7"></a><var>7.7</var>(1) if its labeling is false or misleading in any particular;<br />
         		<a id="pl.7.8"></a><var>7.8</var>(2) if in package form and not dispensed pursuant to a prescription unless it bears <br />
         		<a id="pl.7.9"></a><var>7.9</var>a label containing (a) the name and place of business of the manufacturer, packer, or <br />
         		<a id="pl.7.10"></a><var>7.10</var>distributor, (b) a statement of identity ingredients, and (c) an accurate statement of the <br />
         		<a id="pl.7.11"></a><var>7.11</var>net quantity of the contents in terms of weight, measure, or numerical count, provided, <br />
         		<a id="pl.7.12"></a><var>7.12</var>however, that under (c) reasonable variations shall be permitted, and exceptions as to <br />
         		<a id="pl.7.13"></a><var>7.13</var>small packages shall be allowed in accordance with the federal act;<br />
         		<a id="pl.7.14"></a><var>7.14</var>(3) if any word, statement, or other information required by or under authority of <br />
         		<a id="pl.7.15"></a><var>7.15</var>this chapter to appear on the label or labeling is not prominently placed thereon with such <br />
         		<a id="pl.7.16"></a><var>7.16</var>conspicuousness (as compared with other words, statements, designs or devices, in the <br />
         		<a id="pl.7.17"></a><var>7.17</var>labeling) and in such terms as to render it to be read and understood by the ordinary <br />
         		<a id="pl.7.18"></a><var>7.18</var>individual under customary conditions of purchase and use;<br />
         		<a id="pl.7.19"></a><var>7.19</var>(4) if it otherwise fails to meet the labeling requirements of the federal act.<br />
         		<a id="pl.7.20"></a><var>7.20</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2014.<br />
         		<br />
         		<a id="bill.0.8.0"></a><a id="pl.7.21"></a><var>7.21</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 8. Minnesota Statutes 2012, section 152.02, subdivision 8b, is amended to read:<br />
         		<a id="pl.7.22"></a><var>7.22</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 8b. <b>Board of Pharmacy; expedited scheduling of additional substances.</b><br />
         		 <a id="pl.7.23"></a><var>7.23</var>(a) The state Board of Pharmacy may, by rule, add a substance to Schedule I provided that <br />
         		<a id="pl.7.24"></a><var>7.24</var>it finds that the substance has a high potential for abuse, has no currently accepted medical <br />
         		<a id="pl.7.25"></a><var>7.25</var>use in the United States, has a lack of accepted safety for use under medical supervision, <br />
         		<a id="pl.7.26"></a><var>7.26</var>has known adverse health effects, and is currently available for use within the state. For <br />
         		<a id="pl.7.27"></a><var>7.27</var>the purposes of this subdivision only, the board may use the expedited rulemaking process <br />
         		<a id="pl.7.28"></a><var>7.28</var>under section 
         <statute_ref>14.389</statute_ref>. The scheduling of a substance under this subdivision expires the <br />
         		<a id="pl.7.29"></a><var>7.29</var>day after the adjournment of the legislative session immediately following the substance's <br />
         		<a id="pl.7.30"></a><var>7.30</var>scheduling unless the legislature by law ratifies the action.<br />
         		<a id="pl.7.31"></a><var>7.31</var>(b) If the board schedules a substance under this subdivision, the board shall notify <br />
         		<a id="pl.7.32"></a><var>7.32</var>in a timely manner the chairs and ranking minority members of the senate and house of <br />
         		<a id="pl.7.33"></a><var>7.33</var>representatives committees having jurisdiction over criminal justice and health policy <br />
         		<a id="pl.8.1"></a><var>8.1</var>and finance of the action and the reasons for it. The notice must include a copy of the <br />
         		<a id="pl.8.2"></a><var>8.2</var>administrative law judge's decision on the matter.<br />
         		<a id="pl.8.3"></a><var>8.3</var>(c) This subdivision expires August 1, 2014.<br />
         		<a id="pl.8.4"></a><var>8.4</var><b>EFFECTIVE DATE.</b>This section is effective the day following final enactment.<br />
         		<br />
         		<a id="bill.0.9.0"></a><a id="pl.8.5"></a><var>8.5</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 9. <b>EDUCATIONAL AWARENESS CAMPAIGN.</b><br />
         		<a id="pl.8.6"></a><var>8.6</var>The commissioner of human services shall increase public awareness of the dangers <br />
         		<a id="pl.8.7"></a><var>8.7</var>of synthetic drugs. The public awareness campaign must be designed to reach a broad <br />
         		<a id="pl.8.8"></a><var>8.8</var>audience, but contain targeted messages for students and young adults. The commissioners <br />
         		<a id="pl.8.9"></a><var>8.9</var>of education, health, human services, and public safety shall cooperate in the formulation <br />
         		<a id="pl.8.10"></a><var>8.10</var>and implementation of the educational awareness campaign.<br />
         		<br />
         		<a id="bill.0.10.0"></a><a id="pl.8.11"></a><var>8.11</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 10. <b>APPROPRIATION.</b><br />
         		<a id="pl.8.12"></a><var>8.12</var>$5,000 in fiscal year 2015 is appropriated from the state government special revenue <br />
         		<a id="pl.8.13"></a><var>8.13</var>fund to the Board of Pharmacy for the costs attributable to the board's cease and desist <br />
         		<a id="pl.8.14"></a><var>8.14</var>authority.<br />
         		<a id="pl.8.15"></a><var>8.15</var><b>EFFECTIVE DATE.</b>This section is effective the day following final enactment.<br />
         		
      </div>